• FDA Grants Breakthrough Therapy Designation for UGN-101 americanpharmaceuticalreview
    October 31, 2018
    UroGen Pharma announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to the Company’s lead product candidate, UGN-101, (mitomycin gel) for....
PharmaSources Customer Service